Skip to main content
Journal cover image

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.

Publication ,  Journal Article
Parikh, KS; Piccini, JP
Published in: Curr Heart Fail Rep
December 2017

PURPOSE OF REVIEW: We explore the pharmacogenomics of the beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent beta-blocker studies. Through this, we will understand how bucindolol may help patients with atrial fibrillation and heart failure with reduced ejection fraction (AF-HFrEF), which carries poor prognosis. RECENT FINDINGS: Retrospective study of the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training trial revealed the interaction between the optimal beta-blocker dose and the ADRB1 Arg389 genotype for HFrEF clinical outcomes. Further, a combinatorial genotype analysis in the Beta-Blocker Evaluation of Survival Trial showed that the Arg389Arg genotype, but not the Gly carrier, was associated with 40% lower mortality risk with bucindolol. Finally, the AF-HFrEF subgroup with the ADRB1 Arg389Arg genotype had greater heart rate reduction and suggestion for mortality benefit. Therapeutic response to beta-blockers varies by beta-blocker mechanism, ADRB1 Arg389 genotype, and clinical setting (AF, HFrEF, AF-HFrEF). The ongoing trial A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure prospectively identifies AF-HFrEF patients with favorable genotype for bucindolol to prevent AF recurrence.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Heart Fail Rep

DOI

EISSN

1546-9549

Publication Date

December 2017

Volume

14

Issue

6

Start / End Page

529 / 535

Location

United States

Related Subject Headings

  • Stroke Volume
  • Receptors, Adrenergic, beta-1
  • Propanolamines
  • Pharmacogenetics
  • Humans
  • Heart Failure
  • Genotype
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Adrenergic beta-Antagonists
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Parikh, K. S., & Piccini, J. P. (2017). Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. Curr Heart Fail Rep, 14(6), 529–535. https://doi.org/10.1007/s11897-017-0364-6
Parikh, Kishan S., and Jonathan P. Piccini. “Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Curr Heart Fail Rep 14, no. 6 (December 2017): 529–35. https://doi.org/10.1007/s11897-017-0364-6.
Parikh KS, Piccini JP. Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. Curr Heart Fail Rep. 2017 Dec;14(6):529–35.
Parikh, Kishan S., and Jonathan P. Piccini. “Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Curr Heart Fail Rep, vol. 14, no. 6, Dec. 2017, pp. 529–35. Pubmed, doi:10.1007/s11897-017-0364-6.
Parikh KS, Piccini JP. Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. Curr Heart Fail Rep. 2017 Dec;14(6):529–535.
Journal cover image

Published In

Curr Heart Fail Rep

DOI

EISSN

1546-9549

Publication Date

December 2017

Volume

14

Issue

6

Start / End Page

529 / 535

Location

United States

Related Subject Headings

  • Stroke Volume
  • Receptors, Adrenergic, beta-1
  • Propanolamines
  • Pharmacogenetics
  • Humans
  • Heart Failure
  • Genotype
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Adrenergic beta-Antagonists